Toxicology – Cobalt

Core Concept

Cobalt toxicity depends heavily on the route, dose, chemical form, and duration of exposure. The two major modern clinical patterns are occupational inhalational disease, which can cause occupational asthma and hard-metal lung disease, and chronic systemic cobalt excess, which can produce cardiomyopathy, neurologic and sensory toxicity, thyroid dysfunction, and polycythemia. An important modern source of systemic cobalt toxicity is the release of cobalt from failing cobalt-containing orthopedic implants, particularly mechanically failing or metal-on-metal hip prostheses.

There is no universally accepted blood cobalt concentration that by itself establishes systemic poisoning, and there is no proven specific antidote. Management therefore centers on identifying and removing the source of cobalt exposure, providing supportive care, treating organ-specific complications, and considering chelation only in selected severe cases with medical-toxicology input.

Cobalt and Vitamin B12

Cobalt is present naturally in vitamin B12 (cobalamin), where it forms the central metal atom of the vitamin molecule. Humans therefore require cobalt indirectly through vitamin B12. However, the nutritional requirement is for cobalamin, not for free cobalt ions or inorganic cobalt salts. Cyanocobalamin and other vitamin B12 preparations do not behave toxicologically like soluble cobalt salts because the cobalt atom remains tightly bound within the cobalamin molecule. Routine vitamin B12 use should therefore not be confused with cobalt poisoning.

Forms and Uses

Cobalt is encountered in metallic form, soluble cobalt salts, cobalt oxides, cobalt-containing alloys, pigments, battery materials, catalysts, and medical-device alloys. Important industries include rechargeable battery manufacture and recycling, hard-metal tool production, aerospace superalloys, jet engines, magnets, electroplating, pigments and ceramics, metal refining, welding, diamond-tool manufacture, and chemical processing.

Modern exposure patterns have changed substantially because cobalt is increasingly important in lithium-ion and other rechargeable batteries, making battery manufacture and recycling significant occupational settings.

Hard Metal

“Hard metal” usually consists of tungsten carbide particles held together by cobalt as a binder. Typical formulations contain large amounts of tungsten carbide with smaller percentages of cobalt. Workers involved in manufacturing, grinding, sharpening, polishing, or recycling hard-metal tools can inhale cobalt- and tungsten-containing dust. This exposure is strongly associated with hard-metal lung disease, a distinctive form of occupational interstitial lung disease.

Orthopedic Implant Exposure

A major modern source of systemic cobalt exposure is wear or corrosion from cobalt-chromium orthopedic implants, particularly metal-on-metal hip systems or mechanically failing modular prostheses. Wear and corrosion can release cobalt and chromium particles and ions into surrounding tissues and the circulation.

Systemic cobalt toxicity from an implant should be considered in a patient with a relevant prosthesis who develops unexplained cardiomyopathy, hearing or visual impairment, neurologic changes, thyroid dysfunction, or polycythemia. Assessment must include the implant itself because blood cobalt measurement alone cannot determine whether revision is required.

Radioactive Cobalt

Radioactive cobalt, particularly cobalt-60, is used in industrial radiation sources and radiotherapy. Exposure to radioactive cobalt creates a radiation and internal-contamination problem in addition to ordinary chemical cobalt toxicity. Such exposures require radiation-medicine expertise and should not be managed as simple heavy-metal poisoning.

Toxic Dose

There is no reliable universal toxic dose for cobalt. Older descriptions suggested that airborne concentrations around 20 mg/m³ were potentially lethal and that chronic exposure around 1–2 mg/m³ could cause fatal pulmonary disease. These figures should not be interpreted as direct human lethality thresholds.

The current NIOSH IDLH of 20 mg/m³ is an emergency occupational-exposure benchmark designed to protect workers from conditions immediately dangerous to life or health. It is not an experimentally established human lethal concentration. Toxicity depends on the chemical form of cobalt, particle size, solubility, route, dose, and duration of exposure.

Pathophysiology

Cobalt toxicity is largely related to biologically available Co²⁺ ions. Soluble salts release cobalt ions directly, while poorly soluble particles may be engulfed by cells and subsequently release cobalt intracellularly. Proposed mechanisms include reactive oxygen species formation, oxidative stress, DNA injury, interference with DNA repair, disruption of calcium- and magnesium-dependent processes, and altered mitochondrial and enzymatic function.

One particularly important mechanism is stabilization of hypoxia-inducible factor-1α (HIF-1α). Cobalt can mimic cellular hypoxia and activate hypoxia-response pathways. This contributes to altered erythropoietin signaling and helps explain cobalt-induced polycythemia.

Cardiovascular Toxicity

Severe chronic systemic cobalt exposure may cause cobalt cardiomyopathy. Patients can develop reduced left ventricular function, dilated cardiomyopathy, heart failure, dysrhythmias, and, in extreme cases, cardiogenic shock. Historically, cobalt cardiomyopathy was described in people exposed to cobalt salts added to beer, but contemporary cases are more often associated with excessive cobalt release from orthopedic implants.

Patients with suspected cobalt cardiotoxicity should undergo ECG evaluation and assessment for structural myocardial injury, including echocardiography and, when appropriate, biomarkers such as troponin and BNP or NT-proBNP.

Hematologic Effects

Cobalt can stimulate red-cell production through effects on hypoxia-responsive pathways and erythropoietin signaling. Chronic systemic exposure may therefore produce polycythemia, with increases in hemoglobin, hematocrit, and red-cell count.

An elevated hematocrit in a cobalt-exposed patient should not automatically be attributed to cobalt. Other causes such as chronic hypoxia, smoking, obstructive sleep apnea, and myeloproliferative disease should also be considered.

Thyroid Toxicity

High systemic cobalt exposure can interfere with thyroid function and may produce hypothyroidism or goiter. Symptoms can include fatigue, cold intolerance, weight gain, and other typical manifestations of hypothyroidism. Thyroid dysfunction is an important clue in systemic cobaltism, especially when accompanied by cardiomyopathy or neurologic symptoms, but it is not present in every patient.

Evaluation should include TSH and free T4 when chronic systemic cobalt toxicity is suspected.

Pulmonary Toxicity

The respiratory tract is a major target of occupational cobalt exposure. Inhalation can cause upper-airway irritation, occupational asthma, hypersensitivity-type reactions, and hard-metal interstitial lung disease. Rarely, very high exposures can produce acute pneumonitis or significant hypoxemia.

Workers with chronic exposure may initially complain of nonproductive cough, exertional dyspnea, wheezing, or chest tightness. Persistent symptoms should prompt pulmonary-function testing and high-resolution CT.

Occupational Asthma

Cobalt is a recognized respiratory sensitizer. Sensitized workers may develop cough, wheezing, chest tightness, and reversible airflow obstruction. Once sensitization has occurred, relatively low subsequent exposure may trigger symptoms.

The most important long-term treatment is elimination or substantial reduction of cobalt exposure, because continued workplace exposure can perpetuate airway inflammation even when bronchodilators are effective.

Hard-Metal Lung Disease

Hard-metal lung disease is an occupational interstitial lung disease associated particularly with exposure to cobalt and tungsten carbide. The interaction between cobalt and tungsten carbide appears to enhance oxidative pulmonary toxicity, so the disease should not be viewed as a simple dose-dependent effect of cobalt alone.

Patients often present with progressive dry cough, exertional dyspnea, fatigue, and later hypoxemia. High-resolution CT may show ground-glass opacities, small nodules, reticulation, consolidation, fibrosis, or honeycombing. Pulmonary-function testing may demonstrate restrictive, obstructive, or mixed abnormalities, with reduced diffusion capacity commonly seen.

Giant Cell Interstitial Pneumonia

The classic histopathologic pattern of hard-metal lung disease is giant cell interstitial pneumonia (GIP). Multinucleated giant cells may be found on bronchoalveolar lavage or lung biopsy and are highly characteristic of hard-metal exposure when the occupational history is compatible.

Not every patient with hard-metal lung disease develops the classic GIP pattern. Other histologic appearances can resemble nonspecific interstitial pneumonia, hypersensitivity pneumonitis, usual interstitial pneumonia, or desquamative interstitial pneumonia.

Acute Inhalational Exposure

Acute exposure to high concentrations of cobalt-containing dust or fumes can cause mucous-membrane irritation, cough, dyspnea, bronchospasm, and rarely acute chemical pneumonitis. Patients should be removed immediately from the source and assessed for hypoxemia and respiratory distress.

Supplemental oxygen should be given when indicated, and inhaled β₂-agonists such as albuterol or salbutamol can be used for bronchospasm. Severe respiratory failure may require ventilatory support.

Dermatologic Toxicity

Cobalt is an important contact sensitizer. Dermal exposure may cause irritant dermatitis, allergic contact dermatitis, or a pruritic papular eruption sometimes called “cobalt itch.” Sensitization can become persistent, and later exposure to small quantities of cobalt may provoke recurrent eczema.

Workers exposed to cement, metal dust, pigments, or tools may also be exposed simultaneously to chromium or nickel. Therefore “cement worker’s eczema” should not automatically be attributed only to cobalt. Formal patch testing can help identify clinically important metal allergy.

Gastrointestinal Effects

Acute ingestion of soluble cobalt salts can cause nausea, vomiting, abdominal pain, and diarrhea. Human data describing severe acute gastrointestinal cobalt poisoning are limited compared with the extensive literature on respiratory and chronic systemic toxicity.

The main priorities after significant ingestion are supportive care, assessment for coingestants, and consultation with a poison center or medical toxicologist when the exposure is substantial.

Neurologic and Sensory Toxicity

High systemic cobalt exposure has been associated with neurologic and sensory abnormalities. Patients may experience paresthesias, cognitive changes, fatigue, mood disturbances, peripheral sensory symptoms, and in severe cases hearing impairment and visual or optic-nerve dysfunction.

This combination of auditory and visual abnormalities is particularly important in patients with suspected prosthetic cobaltism. Appropriate assessment may require neurology, audiology, ENT, ophthalmology, or neuro-ophthalmology consultation.

Renal Effects

The kidneys contribute importantly to cobalt elimination, so impaired renal function may reduce clearance and increase systemic cobalt burden. Renal dysfunction has also been reported among patients with systemic metal-ion exposure.

Older descriptions gave substantial emphasis to cobalt-associated glomerulonephritis, but this is not one of the most characteristic modern clinical manifestations of cobalt toxicity.

Carcinogenicity

Modern carcinogenicity classifications differ from older descriptions. Cobalt metal and soluble cobalt(II) salts are classified by IARC as Group 2A, probably carcinogenic to humans. Cobalt(II) oxide is classified as Group 2B, possibly carcinogenic to humans, while some other cobalt compounds remain Group 3, meaning not classifiable regarding carcinogenicity in humans.

It is therefore inaccurate to assign one carcinogenic classification to every cobalt compound. Occupational exposure reduction remains important, particularly for metal and soluble cobalt compounds.

Diagnosis

The diagnosis of cobalt toxicity requires correlation between exposure history, route, cobalt concentration when appropriate, and organ-specific findings. A detailed history should address hard-metal work, tool grinding, welding, battery manufacturing or recycling, pigment production, metal refining, cement exposure, cobalt-containing supplements, and orthopedic implants.

In any patient with otherwise unexplained cardiomyopathy, polycythemia, hypothyroidism, hearing or visual impairment, and a cobalt-containing prosthesis, systemic cobaltism should be considered.

Laboratory Evaluation

For acute significant exposure, testing may include CBC, electrolytes, bicarbonate, glucose, renal function, and liver enzymes according to the clinical picture. Significant respiratory disease may require pulse oximetry, blood gases, and chest imaging.

For chronic or systemic cobaltism, evaluation should include CBC and hematocrit, renal function, electrolytes, TSH and free T4, ECG, and organ-specific testing. Suspected cardiomyopathy may require troponin, BNP or NT-proBNP, echocardiography, and occasionally cardiac MRI.

Patients with neurologic symptoms may need detailed neurologic evaluation, while visual or auditory complaints warrant ophthalmologic and audiologic testing.

Blood Cobalt Measurement

For suspected metal-on-metal or cobalt-containing implant exposure, EDTA-anticoagulated whole blood measured by a validated ICP-MS method is preferred. Specimen type matters, and serum, plasma, and whole-blood cobalt values should not be compared interchangeably.

There is no universally accepted blood cobalt concentration at which systemic toxicity definitely begins. Many severe prosthetic cobaltism cases have involved concentrations above 100 μg/L, but this is not an absolute diagnostic threshold.

Likewise, the widely discussed level of 7 μg/L in implant surveillance is not a universal toxicity threshold. Patients may be asymptomatic above this concentration, while clinically important local implant problems can occur below it. Clinical assessment and implant evaluation remain essential.

Urinary Cobalt

Urinary cobalt can help document recent systemic or occupational exposure and is commonly used in occupational biomonitoring. However, the concentration depends on timing, renal function, and exposure pattern and should not be interpreted as a stand-alone measure of toxicity.

The old statement that “normal urinary cobalt is 0.1–0.2 μg/L” should not be used as a universal modern reference range. Laboratory-specific and occupational reference values should be used instead.

Evaluation of Hard-Metal Lung Disease

Patients with suspected hard-metal lung disease should undergo a detailed occupational history, pulmonary-function testing, and high-resolution CT of the chest. Bronchoscopy with bronchoalveolar lavage or lung biopsy may be required when diagnosis remains uncertain or when giant-cell interstitial pneumonia needs to be confirmed.

Treatment – Remove the Source

The single most important intervention in chronic cobalt toxicity is:

Identify and eliminate the cobalt source.

Workers with suspected cobalt-induced asthma, dermatitis, or lung disease should be removed from continued exposure until proper occupational evaluation is completed.

In prosthetic cobaltism, source control often means evaluation for orthopedic revision or removal of the failing cobalt-containing implant. Chelation alone is unlikely to provide durable benefit if cobalt continues to be released from the prosthesis.

Treatment of Acute Inhalation

After acute inhalation, the patient should be moved to fresh air. Supplemental oxygen is given for hypoxemia, and inhaled β₂-agonists are appropriate for bronchospasm. Severe respiratory failure should be treated with standard ventilatory support.

Systemic corticosteroids may be appropriate when the presentation resembles a significant asthma exacerbation or inflammatory interstitial lung disease, but they are not a cobalt-specific antidote.

Treatment of Hard-Metal Lung Disease

The cornerstone of hard-metal lung disease treatment is complete cessation of exposure. Systemic corticosteroids are commonly used in clinically significant inflammatory disease and may improve symptoms, imaging, and pulmonary function, although evidence is based mainly on observational studies and case series rather than randomized trials.

Advanced fibrotic disease may not fully reverse. Patients with progressive disease require specialist interstitial-lung-disease management, and rare severe cases may eventually require lung transplantation.

Skin and Eye Decontamination

For dermal exposure, contaminated clothing should be removed and the skin washed thoroughly with soap and water. Allergic dermatitis is treated with exposure avoidance and standard dermatologic therapy, often including topical corticosteroids.

Ocular exposure requires immediate copious irrigation with water or saline. Persistent pain, photophobia, corneal injury, or visual change warrants ophthalmologic assessment.

Gastrointestinal Decontamination

Induced vomiting and ipecac should not be used. The historical recommendation for routine ipecac is obsolete.

Activated charcoal is not established as useful for isolated cobalt ingestion because there are no good cobalt-specific human outcome data. Routine gastric lavage is also obsolete and would only be considered under exceptional circumstances involving a very recent, massive, potentially lethal ingestion after airway protection and specialist consultation.

Whole-bowel irrigation may occasionally be discussed after a very large ingestion of radiopaque metallic cobalt or other retained cobalt-containing solid material, but it is not routine therapy.

Antidote and Chelation

There is no established specific antidote for cobalt poisoning. Several chelators have been studied or used in case reports, including CaNa₂EDTA, succimer, DMPS, DTPA, and N-acetylcysteine. However, evidence is sparse and largely case-based.

Chelation should therefore not be started merely because a cobalt concentration is elevated. It is best reserved for selected severe cases after consultation with a medical toxicologist, particularly when the source has already been removed or controlled.

Dimercaprol (BAL) is not standard therapy for cobalt poisoning.

Hemodialysis

Hemodialysis is not an established method for reversing cobalt toxicity in patients with normal renal function. Once cobalt has distributed into tissues, extracorporeal removal may not substantially change clinical outcome.

Dialysis should therefore be used mainly for conventional indications such as severe kidney failure, refractory hyperkalemia, metabolic acidosis, or volume overload rather than solely to remove cobalt.

Cardiomyopathy Management

Cobalt-associated cardiomyopathy should be managed according to standard cardiology and critical-care principles. Treatment may include oxygen when required, diuretics for congestion, guideline-directed heart-failure therapy, vasopressors or inotropes for cardiogenic shock, and mechanical circulatory support in extreme cases.

The crucial toxicologic intervention remains removal of ongoing cobalt exposure, particularly revision of a failing implant when clinically indicated.

Polycythemia and Hypothyroidism

Cobalt-associated polycythemia generally improves after the exposure source is removed. Management should also investigate alternative causes of erythrocytosis.

Patients with clinically significant hypothyroidism should receive standard thyroid replacement therapy when appropriate while the cobalt source is identified and controlled.

Occupational Management

Workers with suspected cobalt-related asthma, dermatitis, or interstitial lung disease should be removed from exposure pending evaluation. Workplace assessment should involve occupational medicine and industrial hygiene, with attention to local exhaust ventilation, engineering controls, respiratory protection, skin protection, workplace monitoring, and process substitution where feasible.

Current Workplace Standards

The current federal OSHA permissible exposure limit for cobalt metal, dust, and fume is 0.1 mg/m³ as an 8-hour TWA. The NIOSH recommended exposure limit is 0.05 mg/m³ as a TWA, and the NIOSH IDLH value is 20 mg/m³.

The 20 mg/m³ IDLH should not be interpreted as a proven lethal concentration. It is a protective emergency-exposure benchmark derived conservatively because robust acute human lethality data are lacking.

Monitoring and Follow-Up

Monitoring should be tailored to the organ systems involved. Respiratory disease requires serial symptoms, PFTs, and imaging when appropriate. Systemic cobaltism may require serial CBC, renal and thyroid function, ECG, echocardiography, neurologic assessment, ophthalmologic testing, audiometry, and repeated whole-blood cobalt concentrations.

Trends in cobalt concentration are generally more informative than a single result, especially after implant revision or other source removal.

Prognosis

Minor acute exposures generally resolve after removal from exposure and supportive care. Allergic contact sensitization may persist indefinitely and recur with very small future exposures.

Occupational asthma may improve after removal from cobalt but can become persistent when diagnosis and exposure cessation are delayed. Hard-metal lung disease has a variable course; inflammatory disease may improve substantially, whereas established pulmonary fibrosis can remain permanent.

Systemic cobaltism may also improve following source removal. Polycythemia and thyroid abnormalities can be reversible, and cardiac function may recover in some patients after implant revision or cessation of exposure. Severe established cardiomyopathy, visual injury, auditory injury, or advanced pulmonary fibrosis may leave permanent deficits.

Important Pitfalls

A major pitfall is assuming that because cobalt occurs in vitamin B12, free cobalt exposure is nutritionally harmless. The body requires cobalamin, not free cobalt ions.

Another important error is thinking cobalt toxicity occurs only in industrial workers. Failing orthopedic implants are now a major clinical source of systemic cobaltism and should be considered when cardiomyopathy, hearing loss, visual impairment, hypothyroidism, cognitive abnormalities, or polycythemia occur in a patient with an appropriate prosthesis.

An elevated blood cobalt concentration does not by itself establish clinical poisoning. There is no universal threshold separating toxic from nontoxic patients, and values such as 7 μg/L or 100 μg/L should not be used as absolute cutoffs.

Serum, plasma, and whole-blood cobalt values are not directly interchangeable. For implant-related assessment, standardized whole-blood testing is preferred.

Chelation is not established routine therapy. Treating a cobalt number without controlling a failing prosthesis or occupational source is unlikely to produce durable improvement.

Hard-metal lung disease should not be described simply as “cobalt pulmonary fibrosis.” The cobalt–tungsten carbide mixture is particularly important, and giant cell interstitial pneumonia is a highly characteristic pathologic clue.

The NIOSH IDLH of 20 mg/m³ should also not be mistaken for a proven lethal concentration. Finally, older recommendations for ipecac, routine gastric lavage, and automatic activated charcoal are obsolete.

High-Yield Toxicology Pearls

Cobalt toxicity should make you think of two main settings: occupational lung disease and systemic cobaltism.

A hard-metal worker with cough and progressive dyspnea should raise concern for cobalt-associated occupational asthma or hard-metal interstitial lung disease. A patient with a cobalt-containing hip prosthesis plus cardiomyopathy, hearing or visual changes, hypothyroidism, neurologic symptoms, or polycythemia should raise concern for prosthetic systemic cobaltism.

The classic hard-metal exposure is tungsten carbide plus cobalt, and the characteristic histologic lesion is giant cell interstitial pneumonia. The first and most important treatment is complete removal from exposure.

Systemic cobalt toxicity can cause cardiomyopathy, polycythemia, hypothyroidism, hearing loss, visual impairment, and neurologic dysfunction. Whole-blood cobalt measured by validated ICP-MS is preferred in implant-related evaluation, but no single cobalt concentration establishes toxicity.

Chelation remains specialist-directed and is not routinely indicated. Hemodialysis is not a reliable cobalt antidote. Acute ingestion should not be treated with ipecac or routine gastric lavage.

Current workplace limits are OSHA 0.1 mg/m³ TWA, NIOSH 0.05 mg/m³ TWA, and NIOSH IDLH 20 mg/m³. The IDLH value is an emergency occupational benchmark, not a human lethal concentration.

The most important principle in chronic cobalt poisoning is:

Find and eliminate the source.